• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Dosage and control of oral anticoagulants: an international collaborative survey.

作者信息

Poller L, Taberner D A

出版信息

Br J Haematol. 1982 Jul;51(3):479-85. doi: 10.1111/j.1365-2141.1982.tb02805.x.

DOI:10.1111/j.1365-2141.1982.tb02805.x
PMID:7104231
Abstract

An international survey of oral anticoagulant dosage has been carried out comparing the mean dosage prescribed in hospitals in 23 countries. In addition, participants using the Quick prothrombin time test were asked to assess the adequacy of dosage of a lyophilized test plasma which was mid-therapeutic using the British Comparative Thromboplastin (BCT). The overall mean dosage proved similar for the groups of laboratories using the Quick test and human brain thromboplastin and Thrombotest although wide differences existed between individual centres. The survey indicated that these discrepancies were due partly to the adoption of different intensities of anticoagulation. In addition, local differences in patients' response to anticoagulants were apparent, e.g. North American centres prescribed a higher mean dose with a more intense therapeutic range than Europeans. Hong Kong physicians appear to prescribe a much lower dose than the rest of the world although the intensity of their treatment is comparable, whereas South African hospitals give moderate doses of warfarin despite a conservative therapeutic range. Such geographical variation in response would invalidate standardization of anticoagulant treatment based on the mean dosage approach.

摘要

相似文献

1
Dosage and control of oral anticoagulants: an international collaborative survey.
Br J Haematol. 1982 Jul;51(3):479-85. doi: 10.1111/j.1365-2141.1982.tb02805.x.
2
The oral anticoagulant saga: past, present, and future.
Clin Appl Thromb Hemost. 2001 Oct;7(4):269-75. doi: 10.1177/107602960100700403.
3
Laboratory monitoring of oral anticoagulant therapy.口服抗凝治疗的实验室监测
Clin Lab Med. 1994 Dec;14(4):813-23.
4
Oral anticoagulant therapy and its control: an international survey.口服抗凝治疗及其控制:一项国际调查。
Thromb Diath Haemorrh. 1975 Nov 15;34(2):419-25.
5
Standardization of anticoagulant control.抗凝控制的标准化
Ric Clin Lab. 1978 Oct-Dec;8(4):237-47.
6
Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?尽管针对抗磷脂综合征进行了“最佳抗凝治疗”,仍出现复发性静脉血栓形成——新型口服抗凝药能否解决这一问题?
Acta Clin Croat. 2010 Dec;49(4):469-77.
7
Standardization of coagulation tests.凝血试验的标准化。
Southeast Asian J Trop Med Public Health. 1999;30 Suppl 3:79-85.
8
Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.口服抗凝剂的起始治疗:使用华法林剂量计算图的理论依据。
Semin Vasc Med. 2003 Aug;3(3):255-60. doi: 10.1055/s-2003-44461.
9
Target-specific oral anticoagulants: should we switch from warfarin?靶向性口服抗凝剂:我们应该停用华法林吗?
Tex Heart Inst J. 2015 Jun 1;42(3):229-33. doi: 10.14503/THIJ-15-5065. eCollection 2015 Jun.
10
Prothrombin time standardization: report of the expert panel on oral anticoagulant control. The International Committee on Thrombosis and Haemostasis, The International Committee for Standardization in Hematology.凝血酶原时间标准化:口服抗凝剂控制专家小组报告。国际血栓与止血委员会,国际血液学标准化委员会。
Thromb Haemost. 1979 Dec 21;42(4):1073-114.

引用本文的文献

1
Thrombosis, Translational Medicine, and Biomarker Research: Moving the Needle.血栓形成、转化医学与生物标志物研究:取得进展
J Am Heart Assoc. 2025 Jan 7;14(1):e038782. doi: 10.1161/JAHA.124.038782. Epub 2024 Dec 24.
2
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.APF2:一种改进的药物基因组变异效应预测集成方法。
Pharmacogenomics J. 2024 May 27;24(3):17. doi: 10.1038/s41397-024-00338-x.
3
Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?
抗凝强度对韩国房颤患者的影响:与西方人群有差异吗?
Korean Circ J. 2020 Feb;50(2):163-175. doi: 10.4070/kcj.2019.0099. Epub 2019 Sep 30.
4
Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.心脏病抗凝治疗的监测:当前检测方法的考量
J Tehran Heart Cent. 2010 Spring;5(2):57-68. Epub 2010 May 31.
5
Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.华法林群体药代动力学和药效学的种族差异。
J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):3-24. doi: 10.1007/s10928-009-9138-4. Epub 2009 Nov 26.
6
Assessment of validity of INR system for patients with liver disease associated with viral hepatitis.评估 INR 系统在病毒性肝炎相关肝病患者中的有效性。
J Thromb Thrombolysis. 2010 Jul;30(1):84-9. doi: 10.1007/s11239-009-0423-2.
7
Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?对于接受华法林中度强度抗凝治疗的中国患者,国际标准化比值(INR)在2.0至3.0之间是最佳水平吗?
Br J Clin Pharmacol. 2005 May;59(5):582-7. doi: 10.1111/j.1365-2125.2005.02361.x.
8
Is the international normalised ratio (INR) reliable? A trial of comparative measurements in hospital laboratory and primary care settings.国际标准化比值(INR)可靠吗?一项针对医院实验室和初级保健机构的对比测量试验。
J Clin Pathol. 1999 Jul;52(7):494-7. doi: 10.1136/jcp.52.7.494.
9
Monitoring oral anticoagulation in primary care.基层医疗中口服抗凝治疗的监测
BMJ. 1996 Jun 8;312(7044):1431-2. doi: 10.1136/bmj.312.7044.1431.
10
Effect of the choice of WHO International Reference Preparation for thromboplastin on International Normalised Ratios.凝血活酶的世界卫生组织国际参考制剂的选择对国际标准化比值的影响。
J Clin Pathol. 1993 Jan;46(1):64-6. doi: 10.1136/jcp.46.1.64.